Mitchell Shirvan
Chief Scientific & Development Officer Silexion Therapeutics
Seminars
Thursday 10th September 2026
SIL204, an Isoform-Selective Pan-KRAS Silencing Stable siRNA with Dual-Delivery Administration for Pancreatic Cancer: Phase 2 Early Safety Findings & Supporting Preclinical Data
11:30 am
- RNA interference (RNAi) gene-silencing technology offers high locus-level precision, reducing off-target effects with implications for a more favorable safety profile than small-molecule inhibitors
- siRNA directly targets oncogenic gene messengers, enabling intervention earlier in the cellular cancer cascade than other KRAS-directed strategies, with important implications for efficacy
- A unique dual-delivery approach maximizes drug exposure at the primary tumor, overcoming the stromal barrier, while simultaneously targeting micrometastases, two critical disease drivers for locally advanced pancreatic cancer with important efficacy and safety implications
